The drug inhibits HER2 dimer formation with other HER family members, such as HER3 and HER1. Genentech is currently studying a combination of both HER2 inhibitors in breast cancer. “With this ...

HER2 testing and targeted therapy are well established in the management of breast cancer. Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of ...

Caption Researchers found in the lab that lapatinib causes HER2 and HER3 to form pairs on cell membranes, priming them in an inactive state (left) so that when growth factors are present, they ...

Reverse-phase protein microarray was used to evaluate protein levels and activation/phosphorylation status of HER family (EGFR, HER2 and HER3) and downstream signaling molecules. The analysis was ...